Akari Therapeutics PLC (NASDAQ:AKTX) – Stock analysts at B. Riley issued their FY2017 earnings per share estimates for shares of Akari Therapeutics in a research note issued to investors on Wednesday. B. Riley analyst M. Kumar expects that the biopharmaceutical company will post earnings per share of ($3.00) for the year. B. Riley currently has a “Neutral” rating and a $3.00 target price on the stock. B. Riley also issued estimates for Akari Therapeutics’ FY2018 earnings at ($1.00) EPS, FY2019 earnings at ($1.00) EPS, FY2020 earnings at ($1.00) EPS, FY2021 earnings at $0.00 EPS and FY2022 earnings at $0.00 EPS.
Akari Therapeutics (NASDAQ:AKTX) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.91.
Shares of Akari Therapeutics (NASDAQ AKTX) opened at $2.32 on Monday. Akari Therapeutics has a twelve month low of $2.06 and a twelve month high of $22.20. The company has a market cap of $27.32, a P/E ratio of -8.29 and a beta of -9.00.
A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd grew its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,334 shares of the biopharmaceutical company’s stock after purchasing an additional 91,322 shares during the quarter. Hikari Power Ltd owned approximately 1.28% of Akari Therapeutics worth $929,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 21.05% of the company’s stock.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.